Midtown Partners & Co, LLC Initiates Coverage and Arrowhead b.i.d. Issues Coverage Update on Hemispherx Biopharma
28 avr. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") reported today that Midtown Partners &Co, LLC initiates coverage of...
Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology
02 mars 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced today that its manufacturing site located in New Brunswick, New...
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
26 janv. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...
Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2014
10 nov. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three and nine months ended September 30, 2014. The net loss (including non-cash...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus
03 nov. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has been informed by USAMRIID scientists that they have in-vitro data...
Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola
20 oct. 2014 12h00 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government...
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
29 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
22 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon(R) and Ampligen(R) Against the Ebola Virus
10 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it expanded its Collaborative Research Agreement to test...
Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014
11 août 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the six months ended June 30, 2014. The net loss (including non-cash effects) was...